Clinical Trials Logo

Filter by:
NCT ID: NCT05497336 Recruiting - Colorectal Cancer Clinical Trials

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Start date: August 18, 2022
Phase: Phase 1
Study type: Interventional

Phase 1b consists of combined dose escalation phase and dose expansion phase. Phase 3 study will compare efficacy and safety of IBI351 combined with cetuximab versus chemotherapy in treatment of KRAS G12C-mutated metastatic colorectal cancer

NCT ID: NCT05497232 Recruiting - Clinical trials for Diabetes Mellitus;Uremia

Clinical Analysis of Simultaneous Pancreas-kidney Transplantation for End-stage Renal Disease Associated With Diabetes Mellitus

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The first pancreas transplantation was performed in 1966, by 2015, more than 40,000 pancreas transplantation have been performed worldwide. Nevertheless, only several Chinese organ transplant centers carry out SPK because of surgery complications. simultaneous pancreas-kidney transplantation is a new and promising therapeutic option for the treatment for type 1 diabetes mellitus patients and end-stage renal disease. the preliminary treatment results are summarized to promote the further development of this work in China.

NCT ID: NCT05497141 Recruiting - Clinical trials for Tricuspid Regurgitation

Dawneo Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System Pivotal Clinical Trial in Patients With Severe Tricuspid Regurgitation

Start date: July 22, 2022
Phase: N/A
Study type: Interventional

To evaluate the safety and effectiveness of Dawneo Neoblazar® transcatheter tricuspid valve edge-to-edge repair system in patients with severe tricuspid regurgitation. This is a prospective, multicenter, randomized, objective performance criteria trial. 98 patients who meet the inclusion criteria will be included in the study. This study will be conducted in in each site as run-in subjects. Subjects who meet the requirements and who voluntarily participate in the trial and sign the informed consent form, will be implanted with the Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System.

NCT ID: NCT05496582 Recruiting - Asthma Clinical Trials

The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma

Start date: November 1, 2022
Phase:
Study type: Observational

Asthma is one of the most common chronic respiratory diseases. Previous study found a series of differentially expressed genes and proteins (transgelin-2, metallothionein-2, ezrin) in asthmatic rat. The aim of the study is to investigate the changes and associations of these gene with asthma in human.

NCT ID: NCT05496543 Recruiting - Clinical trials for Constipation - Functional

Acupuncture for Functional Constipation in Older Adults

Start date: October 10, 2022
Phase: N/A
Study type: Interventional

Through a scientific and standardized randomized controlled study, we observe the effectiveness and safety of acupuncture in the treatment of functional constipation in the elderly through the method of "nourishing kidney and dredging Fu organs".

NCT ID: NCT05496023 Recruiting - Clinical trials for Coronary Artery Disease

Angiography-derived FFR GPS in Predicting Post-PCI Physiological and Clinical Outcomes

Angio-GPS
Start date: January 1, 2017
Phase:
Study type: Observational

To investigate the feasibility of physiological map generated from angiography-derived fractional flow reserve (FFR) (angio-FFR) pullback and its value in predicting physiological and clinical outcomes after stenting.

NCT ID: NCT05495893 Recruiting - Lupus Nephritis Clinical Trials

MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN

MyCITS
Start date: July 25, 2022
Phase: Phase 4
Study type: Interventional

A prospective, randomized, multicenter, open-label, parallel-arm Study to compare effectiveness of mycophenolate mofetil versus cyclophosphamide in the Induction Therapy of pediatric patients with Active Proliferative Lupus Nephritis in Chinese population

NCT ID: NCT05495828 Recruiting - B-cell Lymphoma Clinical Trials

Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

Start date: November 10, 2023
Phase:
Study type: Observational

To evaluate the safety and effecacy of Orelabrutinib therapy in patients with relapsed or refractory B-cell lymphoma (including R /rCLL/SLL and R /rMCL) who are intolerant to ibrutinib/zanubrutinib or other BTK inhibitors

NCT ID: NCT05495724 Recruiting - Clinical trials for Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

Disitamab Vedotin Combined With Tislelizumab for Her2 Overexpressing High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Start date: July 23, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II study to determine the safety and efficacy of Disitamab Vedotin when given in combination with Tislelizumab as treatment for patients with Her2 overexpressing high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not completely resectable. Patients will receive treatment with Disitamab Vedotin in combination with tislelizumab every 3 weeks for 4 treatment cycles over 12 weeks followed by transurethral resection biopsy.

NCT ID: NCT05495711 Recruiting - Infertility, Female Clinical Trials

hUC Mesenchymal Stem Cells (19#iSCLife®-UT) Therapy for Patients With Thin Endometrial Infertility

Start date: August 1, 2022
Phase: Phase 1
Study type: Interventional

To explore the therapeutic effect and safety of human umbilical cord mesenchymal stem cells on thin endometrial infertility and to explore whether human umbilical cord mesenchymal stem cells using collagen as the carrier can promote endometrial growth, reduce the recurrence rate of intrauterine adhesion, increase the clinical pregnancy rate, improve the pregnancy outcome, and study its safety.